Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · May 08, 2023

Long-Term Efficacy and Safety of Avalglucosidase Alfa Therapy in Patients With Late-Onset Pompe Disease

JAMA Neurology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Neurology
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial
JAMA Neurol 2023 Apr 10;[EPub Ahead of Print], PS Kishnani, J Diaz-Manera, A Toscano, PR Clemens, S Ladha, KI Berger, H Kushlaf, V Straub, G Carvalho, T Mozaffar, M Roberts, S Attarian, YH Chien, YC Choi, JW Day, S Erdem-Ozdamar, S Illarioshkin, O Goker-Alpan, A Kostera-Pruszczyk, AT van der Ploeg, K An Haack, O Huynh-Ba, S Tammireddy, N Thibault, T Zhou, MM Dimachkie, B Schoser

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading